View Post

Novel cancer treatment wins endorsement of FDA advisers

In In The News by Barbara Jacoby0 Comments

By: Laurie McGinley From: washingtonpost.com Food and Drug Administration advisers on Wednesday enthusiastically endorsed a first-of-its-kind cancer treatment that uses patients’ revved-up immune cells to fight the disease, concluding that the therapy’s benefits for desperately ill children far outweigh its potentially dangerous side effects. The unanimous recommendation from the Oncologic Drugs Advisory Committee means the treatment could be approved by the FDA …

View Post

Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer

In In The News by Barbara Jacoby0 Comments

From: PR Newswire — Physicians now have the option of prescribing Kisqali and Femara together in one convenient co-pack — Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay — Approval comes less than two months after Kisqali received US FDA approval  Novartis announced today that the US Food and Drug Administration (FDA) has approved the …

View Post

First come, first served: Novartis finalizes CAR-T application, claims priority review

In In The News by Barbara Jacoby0 Comments

By: Juliet Preston From: MedCity News Novartis has made good on its promise to submit a biologics license application (BLA) for its lead CAR-T candidate in the first quarter of the fiscal year. With two days to spare, no less. According to a statement released on Wednesday, the FDA has accepted the submission and granted Novartis a priority review. That …

View Post

Cota Healthcare Announces Major Multi-Year Collaboration With Global Pharmaceutical Leader To Advance Innovative Therapies For Breast Cancer Patients

In In The News by Barbara Jacoby0 Comments

Cota Healthcare, the leading data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients. As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will …

View Post

Novartis chases rivals with next wave of cancer immunotherapy

In In The News by Barbara Jacoby0 Comments

From: reuters.com Novartis (NOVN.S), lagging some other big drugmakers in the first wave of immunotherapy drugs that are revolutionizing cancer treatment, hopes to catch up by focusing on the next wave of immune system-boosting medicines. Setting out its research objectives in slides for a press conference on Wednesday, it said it aimed for “a leadership position in oncology” by focusing …

View Post

Encouraging Results For Ribociclib In Advanced Breast Cancer

In In The News by Barbara Jacoby0 Comments

By: Elaine Schattner From: forbes.com At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is clearly active in hormone receptor-positive (ER+ or PR+) breast cancer. The findings of the MONALEESA trial were published in the NEJM. The main result is that for the most …

View Post

Novartis survey published in The Breast Journal reveals major gaps in treatment discussions between metastatic breast cancer patients and doctors

In In The News by Barbara Jacoby0 Comments

89% of metastatic breast cancer patients surveyed feel it’s important to discuss a long-term treatment “roadmap” with their doctor at initial diagnosis, yet 43% report not having that conversation1 Patients seek comprehensive dialogue with oncologists to understand treatment options and quality of life issues throughout the course of their disease1   Results led to a community-endorsed personalized discussion guide to help …

View Post

Cell Medica, Baylor partner on next-gen CAR-T cancer therapies

In In The News by Barbara Jacoby0 Comments

By: Ben Adams From: fiercebiotech.com London-based Cell Medica, one of last year’s Fierce 15, has signed a pact with Houston’s Baylor College of Medicine to find and develop next-gen tech for engineering immune cells in tumors. In a joint statement, the two saw the “ground-breaking” co-development partnership will see Cell Medica gain an exclusive license over several Baylor cell and …

View Post

Here’s What’s Next For Cancer-Killing T-Cells After Strong ASCO Showings

In In The News by Barbara Jacoby0 Comments

By: Arlene Weintraub From: forbes.com The big news about chimeric antigen receptor T-cells (CARTs) at the American Society of Clinical Oncology meeting that just concluded in Chicago is that there was no earth-shattering news. Some analysts feared that predictions of FDA approvals as early as 2017 would prove overly optimistic for the technology, which involves removing immune-boosting T-cells from patients, …

View Post

A Novel Cell Therapy Untested in Humans Saves Baby With Cancer

In In The News by Barbara Jacoby0 Comments

By: Andrew Pollack From: nytimes.com A baby girl who was close to dying from cancer has been rescued by a cell therapy envisioned as a “one size fits all” treatment that had never been tested in people, doctors reported on Thursday. The development is significant because it indicates that cell therapies, which represent an exciting new front in the battle …